



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE TEAMS MEETING 19th JANUARY 2022

PRESENT:

Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL CCG
Dr S Ramtoola (SR)	Consultant Physician, ELHT (Chairperson)
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mr J Vaughan (JV)	Senior Medicines Commissioning Pharmacist NHS EL/BwD
Ms F Iqbal (FI)	Senior Pharmacist NHS BwD CCG
Mr U Akram (UA)	Deputy Lead Pharmacist, LSCFT
Dr T McKenzie	GP East Lancashire
Ms Ana Batista	Medicines Information Pharmacist ELHT
Mr Chris Woods	Head of Contracting and Costing, Finance

IN ATTENDANCE:

Ms L Prince	Medicines Management Technician, EL CCG
-------------	---

2022/001: APOLOGIES:

None received

2022/002: DECLARATION OF INTEREST – None declared

2022/003: MINUTES OF DECEMBER Teams MEETING:

Amendment to Page 1 – Title (UA) to be amended

Item 2021/148 – amend 2.5% to 0.5% on the following sentence:”

It was acknowledged that the 0.5% ointment was useful in young children”

2022/004: MATTERS ARISING:

- a. **2021101b:** ELMMB Membership ongoing – deferred to February meeting
- b. **2021/123: Fidaxomicin** supply options: update – Pathway, including supply options and costings across all sectors to be available at February meeting
- c. **2021/133: Klisyri** – clear Guidance/Position Statement for GPs to be developed by dermatology and ELHT pharmacy: deferred to February meeting.
- d. **2021/137b: Trazodone 50mg/5ml oral solution:** capsule formulation does not allow for easy titration of decreasing or small doses. Secondary care report use of the licensed liquid 12 times from January2021-November2021 and Primary Care averages about 30 items per month, the use being in Care Homes.



Members agreed to include the licensed liquid as 'Green restricted' to formulary. Its use will be specific to titration when reducing/discontinuing treatment and for patients with swallowing difficulties.

Resolved: Trazodone 50mg/5ml oral solution to be included in formulary as 'Green Restricted' use.

- e. **2021/147 item a/b: Utrogestan (Oral 100mg Capsules) /Topical oestrogen products.** Place in therapy, products and use not clear in LSCMMG HRT guidance. AB to invite consultant gynaecologist to next meeting to discuss use and place in therapy of the products.

Evidence and information as to products and place in therapy to be brought to next meeting

- f. **2021/147 item c: Ozurdex 700 micrograms intravitreal implant in applicator.**

Item closed: Blueteq to be updated by CSU.

2022/005 a. New product request - Ketofall (Ketotifen) single – dose container containing 0.1mg of Ketotifen in 0.4ml. Requested by Dr Usmani, Consultant Ophthalmic and Corneal Surgeon, for seasonal allergic conjunctivitis from age 3 and above. The product is preservative free and is not for continuous use. It is proposed that it is used as a second line option for those patients requiring a preservative free formulation.

Resolved: Ketofall to be included in formulary as second line option when a preservative free product is required. **Traffic Light:** GREEN restricted

2022/005 b. New product request - Xiapex (collagenase Clostridium histolyticum) 0.9 mg Powder and solvent for solution for injection. This product is unavailable as the marketing authorisation has been withdrawn. It was previously provided as part of a Clinical Trial in ELHT(now closed) that has one treatment vial remaining. The request is from orthopaedics to use this remaining vial to treat Dupuytren's contracture for a patient identified as suitable for the treatment [unlicensed use].

Resolved: Use of Xiapex acknowledged by ELMMB

2022/006 FORMULARY UPDATES:

Zonisamide liquid: requested by paediatric lead pharmacist for epilepsy refractory to first line anti-epileptics; the capsules are not suitable for dosing in younger patients. There were safety concerns raised with the required titration of doses and a need for an appropriate pathway should prescribing be continued in primary care. It was decided to add to formulary as RED traffic light and to ask for number of patients that are currently going through the IMOT service to be brought for discussion at the February meeting.

Action: Potential/current number of patients going through IMOT service

Resolved: Zonisamide liquid to be added to formulary as RED, whilst awaiting further information. **Traffic Light:** RED



Phytomenadione 1mg capsules: requested by paediatric lead pharmacist. Current formulary product is unlicensed [Orakay]. Request to switch to licensed version Neokay®.

Resolved: Neokay to be added to formulary and Orakay [unlicensed] removed
Traffic Light: AMBER

Epesri: [ethosuximide 250mg capsules] Ethosuximide has become the product of choice for patients since the valproate alert and primary care has seen an increase in prescribing in both tablets and liquid formulations. Requested that Epesri® capsules replace the existing formulary product as the cost-effective product of choice on formulary. It was also agreed that the possibility of supplying the liquid version of ethosuximide through IMOT be explored.

Resolved: Change to branded product Epesri® acknowledged by ELMMB.
ACTION: Prescribing of liquid formulation through IMOT service to be explored

2022/007: LSCMMG CONSULTATIONS (February LSCMMG)

Primary Care Management of Menopause.

It was noted that the document needs to provide information on specific products of choice. It was suggested that the second 'box' on page three could be removed completely a reference to T2D isn't required and it would not be appropriate to refer. Also on page 3 testosterone should be less prominent i.e. small print as it carries risk. There were also concerns raised as to reference of using clonidine second line to gabapentin, which is addictive. LR has asked LMMG for a Patient information Leaflet to highlight the safety issues. It would also be useful to include contraindications in the document.

Comments to be fed back to LSCMMG

2022/008: LSCMMG RECOMMENDATIONS (from December LSCMMG)

Overactive Bladder Guidance – New version awaiting further information prior to publishing.

Resolved: Acknowledged by ELMMB, await final version

2022/009: Other items

Commissioning recommendations for national procurement for direct acting oral anticoagulants (DOACs)_January 2022 – for information. There are no plans to actively switch patients to edoxaban: the recommendation will apply to all new patients being initiated on a DOAC. VG to share the document with Cardiology and stroke consultants and appropriate teams. The formulary will be updated to reflect the position ELHE is adopting

2022/010 Other items

Syringe Pump Policy – updated



Resolved: Updated Syringe Pump Policy acknowledged by ELMMB

2022/011: Other items

Non-Medical Prescribing Policy – updated

Resolved: Update Non-Medical Prescribing Policy acknowledged by ELMMB

2022/012: NICE Guidance – November 2021

Headaches in over 12s: diagnosis and management (CG150) last updated 17th December 2021, first published 19th September 2012

Resolved: item acknowledged by ELMMB

2022/013: NICE RECOMMENDATIONS from December 2021

Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Liraglutide for managing obesity in people aged 12 to 17 years (TA749) terminated appraisal.

Traffic Light: BLACK

Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (TA750) terminated appraisal.

Traffic Light: BLACK

Dupilumab for treating severe asthma with type 2 inflammation (TA751) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA752) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Cenobamate for treating focal onset seizures in epilepsy (Ta753) is recommended as an option by NICE. Approved in line with NICE.

CCG Commissioned

Traffic Light: RED

Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Risdiplam for treating spinal muscular atrophy (TA755) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA756) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED



STANDING ITEMS

2022/014: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA MEDICINES MANAGEMENT GROUP (LSCMMG) MINUTES – December 2021

Minutes acknowledged

2022/015: FOR ACTION/INFORMATION:

- a) Drugs and Therapeutics Committee Meeting Minutes from 26th November 2021
- b) Action Tracker from the Drugs and Therapeutics Committee Meeting 26th November 2021 (003)
- c) Drugs and Therapeutics Committee Meetings 2022 To March 2023

Minutes acknowledged

2022/016: FOR ACTION/INFORMATION:

Antimicrobial Stewardship Committee (ASC) – November 2021 Minutes

Minutes acknowledged

2022/017: additional item

FOC scheme application form - Sacituzumab Govetican.

Resolved: Acknowledged by ELMMB

2022/018: AOB

LR requested that the current Neutralising monoclonal antibodies NMABs for non-hospitalised patients with COVID-19 are acknowledged and included in the formulary.

Resolved: Sotrovimab, Molnupiravir and Casirivimab & imdevimab acknowledged by ELMMB

Traffic Light: RED

**DATE OF NEXT MEETING – Wednesday 23rd February 2022 12.45pm via
'Microsoft Teams'**



**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 19th JANUARY 2022

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2021/101b	ELMMB Membership VG to approach Divisional directors to be asked to review their members and suggest a nominated person to attend future meetings.	VG	Feb 22
2021/123	Fidaxomicin – pathway, supply options and costings.	VG/JV/SM	Feb 22
2021/133	Klisyri – draft Guidance/Position Statement to be brought to next meeting. VG to follow up with dermatology colleagues.	VG	Feb 22
2021/147 (a,b)	Utrogestan® & Topical Oestrogen Products – further information on products and place in therapy to be requested from gynaecology	AB	Feb 22
2021/148	Eosinophilic oesophagitis: Supporting guidance/PIL required for use of Flovent in Primary Care. To be developed by ELHT.	JE	Feb 22
2022/006a	Zonisamide liquid: Further information requested – number of patients potentially/currently going through IMOT service	VG/AA	Feb 22
2022/006c	Ethosuximide liquid: Prescribing of liquid formulation through IMOT service	VG	Feb 22
2022/009	National procurement for DOACs ELMMB website to reflect position ELHE is adopting for DOACs.	JV/LP	Feb 22